​Pharmacology - Saquinavir

​Pharmacology -  Saquinavir 
This reversible inhibitor blocks the viral-specific protease, which is responsible for cleaving precursor viral proteins during budding and assembly to produce the structural and functional proteins of newly formed virions.

Acute first-pass metabolism occurs after oral administration. Half life is 12 hours.

Use in Clinical Settings
infection with HIV-1 while taking other antiretrovirals (ARTs). The virus can be reduced by around 50% when passed from mother to foetus.
 
Negative Impacts
difficulties with the gastrointestinal tract, sinusitis, insulin resistance, and lipodystrophy.